Related Experiment Video

Updated: May 26, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Platelet function profile post-clopidogrel therapy in patients with type 2 diabetes undergoing coronary stent

Abeer Attia Saad1, Eman Abdel Rahman Ismail, Yasser Wagih Darwish

  • 1Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|December 8, 2011
PubMed

Insights

Platelet dysfunction is higher in diabetic patients after coronary stenting, increasing complication risks. Poor glycemic control directly impacts platelet reactivity, highlighting a key factor in post-procedure outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Hematology

Background:

  • Platelet dysfunction increases thromboischemic risks post-percutaneous coronary intervention (PCI), especially in type 2 diabetes.
  • The impact of glycemic control on platelet reactivity remains largely uncharacterized.

Purpose of the Study:

  • To assess adenosine diphosphate-induced platelet aggregation and P-selectin expression in diabetic and nondiabetic patients undergoing PCI.
  • To evaluate platelet reactivity as a predictor of post-PCI complications and its relationship with glycemic control.

Main Methods:

  • Studied 90 patients (56 diabetic, 34 nondiabetic) receiving clopidogrel during coronary stent implantation.
  • Measured platelet aggregation and P-selectin expression via aggregometry and flow cytometry.
  • Correlated platelet function with clinical factors and glycemic control (hemoglobin A1c).

Main Results:

  • Diabetic patients exhibited significantly elevated posttreatment platelet reactivity compared to nondiabetics.
  • Elevated reactivity was linked to smoking, hypercholesterolemia, overweight, and ischemic events.
  • A linear association was observed between hemoglobin A1c and platelet reactivity in diabetic patients.

Conclusions:

  • Posttreatment platelet reactivity is a significant risk factor for ischemic events after PCI in diabetic patients.
  • Low responsiveness to clopidogrel is associated with adverse outcomes in this population.
  • Glycemic control directly influences platelet reactivity, impacting cardiovascular outcomes.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...